Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETs

Go back to Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETs
Bristol-Myers Squibb (NYSE: BMY) Delayed: 61.12 -0.56 (0.91%)
Previous Close $61.68    52 Week High $77.12 
Open $61.50    52 Week Low $49.03 
Day High $61.81    P/E 39.69 
Day Low $60.69    EPS $1.54 
Volume 9,015,491